Search
forLearn
5 / 801 resultslearn ABN Complex
learn nonspecific group of Fibronectins
learn NMN
learn nettle
Research
5 / 193 results
research 1430 Modeling the onset of senescence associated secretory phenotype predicts therapeutic targets
The research found that blocking a gene called NEMO can potentially prevent harmful effects of aging at the cellular level.
research A probabilistic Boolean model on hair follicle cell fate regulation by TGF-β
TGF-β and TNF influence hair follicle cell fate, with TNF being more effective in triggering cell death.
research DEEP REINFORCEMENT LEARNING FOR SCALABLE CONTROL OF BOOLEAN MODELS IN THE CONTEXT OF CELLULAR REPROGRAMMING
pbn-STAC effectively finds strategies for cellular reprogramming using deep reinforcement learning.
research Trichoscopy and Computational Models for Hair and Scalp Disorders: Image Analysis, Quantification, and Clinical Integration
AI in hair and scalp analysis shows promise but lacks real-world clinical integration and validation.
research Identifying molecular targets for reverse aging using integrated network analysis of transcriptomic and epigenomic changes during aging
Curcumin may help reverse aging by targeting specific genes.
Community Join
5 / 1000+ resultscommunity I built a free Al-powered hair transplant simulator for the community, would love your feedback!
A user created a free AI-powered hair transplant simulator to help visualize post-transplant results, seeking feedback and offering it as a tool for clinics. Users discussed its usefulness, limitations, and the requirement for email and phone verification to prevent abuse.
community What's the deal with Spectral.DNC-N/'nanoxidil'?
Nanoxidil is considered to have better absorption and fewer side effects than minoxidil, with added DHT blockers. The user is questioning if switching to the more expensive Spectral.DNC-N is worthwhile compared to cheaper options like Kirkland minoxidil.
community I created a video that breaksdown everything there is too know about GT20029
The conversation discusses a video about GT20029, a treatment for hair loss, and its comparison to KX826. Users express interest in the video's effectiveness and potential, and praise its informative content.
community How is the GT20029 different to pyrilutamide as an androgenic antagonist
GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.
community Where are we with GT20029 ? Realistic Timeline ?
GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.